Novavax Inc.

NVAX
Sinnathurai v. Novavax, Inc. et al., (Case No. 8:21cv02910), D. Md.

On October 19, 2021, after the market closed, Politico published an article, titled “’They Rushed the Process’: Vaccine Maker’s woes hamper global inoculation campaign”, alleging manufacturing and purity problems in Novavax’s process to produce Covid-19 vaccinations for COVAX, an international consortium working to provide two billion doses to middle and low income countries. Previously, the U.S. government invested $1.6B in Novavax in 2020, the most devoted to any vaccine manufacturer at the time.

On this news shares of Novavax fell over 20% in premarket trading on October 20, 2021.

Lead Plaintiff deadline
January 11, 2022
class period
March 2, 2021
to
October 19, 2021
Case Documents
No documents available. Contact us if you need a case document.